![2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carbo…](https://static.cymitquimica.com/products/3D/img/FM102909.png "Clique para ampliar")
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid
CAS: 1372540-25-4
Ref. 3D-FM102909
| 5mg | Descontinuado | ||
| 10mg | Descontinuado | ||
| 25mg | Descontinuado |
Informação sobre produto
Nome:
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid
Descrição:
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid (BIC) is a strain that is categorized as a cancer drug. It has been synthesized in the laboratory and has been shown to bind to the bRaf protein, inhibiting its activity. BIC is also known as a stereoisomer because it has two different forms, L and D. The symbol for this drug is "BIC". This drug discriminates between healthy cells and cancer cells by selectively targeting those with mutated bRaf proteins. The parameter of this drug that is quantized is its effect on cancer cells. BIC's virulent effects may be due to its ability to inhibit the synthesis rate of antibodies in the body.
Aviso:
Os nossos productos estão destinados exclusivamente para uso em laboratório. Para qualquer outra aplicação, por favor entre em contacto.
Marca:
Biosynth
Armazenamento a longo prazo:
Notas:
Propriedades químicas
Peso molecular:
433.42 g/mol
Fórmula:
C22H22F3N3O3
Pureza:
Min. 95%
MDL:
Ponto de fusão:
Ponto de ebulição:
Ponto de inflamação:
Densidade:
Concentração:
EINECS:
Merck:
Código HS:
